Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Unum Therapeutics Inc (UMRX) USD0.001

Sell:$1.97 Buy:$2.00 Change: $0.02 (0.99%)
NASDAQ:0.11%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$1.97
Buy:$2.00
Change: $0.02 (0.99%)
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$1.97
Buy:$2.00
Change: $0.02 (0.99%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Unum Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the developing and commercializing of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. Its proprietary technology, called antibody-coupled T cell receptor (ACTR), is a universal, engineered cell therapy that is used in combination with a range of tumor-specific antibodies to target different tumor types. The Company's product candidates are composed of ACTR T cells co-administered with approved and commercially available antibodies or antibodies in preclinical or clinical development. The ACTR platform to transform cancer treatment and deliver patient cures in many different hematologic and solid tumor cancers, improving upon current cell therapies. The Company's product pipeline that includes clinical stage product candidates: ACTR087, ACTR087 (SEA-BCMA) and ACTR707.

Contact details

Address:
200 Cambridgepark Dr Ste 3100
CAMBRIDGE
02140-2307
United States
Telephone:
+1 (617) 9455576
Website:
https://www.unumrx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
UMRX
ISIN:
US9032141049
Market cap:
$61.32 million
Shares in issue:
30.66 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Bruce Booth
    Independent Chairman of the Board
  • Charles Wilson
    President, Chief Executive Officer, Director
  • Matthew Osborne
    Chief Financial Officer
  • Geoffrey Hodge
    Chief Technology Officer
  • John Green
    Principal Accounting Officer, Controller, Senior Director of Finance
  • Seth Ettenberg
    Chief Scientific Officer
  • Mert Aktar
    Head of Business and Corporate Development
  • Jessica Sachs
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.